Black Harmony, Glavey Siobhan
Department of Haematology, Beaumont Hospital, Dublin D09 V2N0, Ireland.
Department of Pathology, Royal College of Surgeons in Ireland, Dublin D02 YN77, Ireland.
Cancer Drug Resist. 2021 Dec 1;4(4):1008-1018. doi: 10.20517/cdr.2021.83. eCollection 2021.
Multiple myeloma (MM) is an aggressive plasma cell malignancy with high degrees of variability in outcome, some patients experience long remissions, whilst others survive less than two years from diagnosis. Therapy refractoriness and relapse remain challenges in MM management, and there is a need for improved prognostication and targeted therapies to improve overall survival (OS). The past decade has seen a surge in gene expression profiling (GEP) studies which have elucidated the molecular landscape of MM and led to the identification of novel gene signatures that predict OS and outperform current clinical predictors. In this review, we discuss the limitations of current prognostic tools and the emerging role of GEP in diagnostics and in the development of personalised medicine approaches to combat drug resistance.
多发性骨髓瘤（MM）是一种侵袭性浆细胞恶性肿瘤，其预后具有高度变异性，一些患者可长期缓解，而另一些患者从诊断起存活时间不到两年。治疗难治性和复发仍然是MM治疗中的挑战，因此需要改进预后评估和靶向治疗以提高总生存期（OS）。在过去十年中，基因表达谱（GEP）研究激增，这些研究阐明了MM的分子格局，并导致识别出预测OS且优于当前临床预测指标的新型基因特征。在本综述中，我们讨论了当前预后工具的局限性以及GEP在诊断和开发对抗耐药性的个性化医学方法中的新兴作用。
